Novo Nordisk - The Pharmaceutical sector

Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Latest News 2013: The Food and Drug Administration has rejected the marketing application of Novo Nordisk for its two new diabetes drugs. Novo Nordisk is the world s biggest insulin maker. The two new drugs which Novo Nordisk has brought are named Tresiba nd Ryzodeg respectively. The reason given by the FDA for rejecting the drugs is that the two new diabetes drugs are considered as degludec products which could increase the composite risk of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and unstable angina by 10% relative to active comparators. Reporters have advanced that the Novo Nordisk had to acknowledge the decision of the FDA despite the fact that the FDA's own advisory committee has approved of the drugs. In-depth reports have revealed that the FDA's advisory committee had voted 8 to 4 in favour of approving the product with a recommendation for cardiovascular outcomes trial post-approval...

Product details

• Assisted by: Edward R. Miller-Jones (Editor), Edwar R Miller-Jones (Editor)
• Publisher: FastBook Publishing
• Languages: English
• Product format: Paperback / Softback
• Released: 01.01.2013
• EAN: 9786130150501
• ISBN: 978-613-0-15050-1
• No. of pages: 156
• Subject: Natural sciences, medicine, IT, technology > Medicine